Mattias Ringh medisinering informasjon.

Mattias Ringh, M.D medisinering informasjon .D., Ph.D., Jacob Hollenberg, M.D., Ph.D., Martin Jonsson, B.Sc., David Fredman, R.N., Per Nordberg, M.D.D., Ingela Hasselqvist-Ax, R.N., Gabriel Riva, M.D., and Leif Svensson, M.D., Ph.D.: Mobile-Phone Dispatch of Laypersons for CPR in Out-of-Medical center Cardiac Arrest Bystander-initiated cardiopulmonary resuscitation before the arrival of emergency-medical-services personnel is certainly associated with an interest rate of survival among patients with out-of-hospital cardiac arrest that is up to 3 x as high as the rate among patients who usually do not receive such assistance.1,2 Low prices of bystander-initiated CPR certainly are a main obstacle to improved survival prices.3 The usual method of increase rates of bystander-initiated CPR has been to train as a lot of the public as possible.4 However, this approach is associated with substantial costs and uncertain results on prices of bystander-initiated CPR.5 By using a mobile-phone positioning program, persons who’ve mobile phones can be located6 and delivered to assist individuals with suspected out-of-medical center cardiac arrest; this process offers been reported in prior simulation and pilot studies.7,8 We hypothesized that the usage of a mobile-phone positioning program to dispatch lay responders who are been trained in CPR to assist individuals with suspected out-of-medical center cardiac arrest would raise the proportion of cases where CPR was performed by trained bystanders.

Fabian, M.D., Pascal Pujol, M.D., Elizabeth Maunsell, Ph.D., Patricia Farmer, M.D., Karen A. Gelmon, M.D., Dongsheng Tu, Ph.D., and Harriet Richardson, Ph.D. For the NCIC CTG MAP.3 Research Investigators: Exemestane for Breast-Cancer Prevention in Postmenopausal Women Estrogens donate to normal breast development but may also promote breast cancer in preclinical models and in women with high circulating plasma estrogen amounts.1-4 To time, chemoprevention of breast malignancy has focused on the selective estrogen-receptor modulators tamoxifen and raloxifene, which exert antiestrogenic effects on the breast, as well as agonist or antagonist effects on other organs.